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Tumor-fighting T cells lose their way
Like a tourist without a map, tumor-fighting T cells have a hard time finding their destination 
without directions. According to Clark et al. (page 2221), dismantling these directions helps skin 
cancer cells hide from killer T cells.
To enter the skin, T cells must grab on to the adhesive molecule E-selectin, which is 
expressed on the endothelial cells lining blood vessels in the skin. The authors now find that 
many of the vessels in skin cancer lesions lack E-selectin, causing beneficial T cells to pass by 
unaware. The tumors were instead populated by suppressive regulatory (T reg) cells, perhaps 
coaxed in by the tumor to safeguard against killer cells that somehow gain access. Both tactics 
have also been seen in other types of human cancer.
Reversing the suppressive effect of T reg cells is one of the beneficial effects of topical 
immune-stimulating drugs like the TLR agonist imiquimod, which is effective in treating certain 
types of skin cancer. Indeed, Clark et al. found that imiquimod treatment reduced both the 
percentages and function of tumor-infiltrating T reg cells. To the authors’ surprise, the drug also 
induced E-selectin expression on tumor vessels, restoring T cell road signs and allowing killer 
T cells to invade the tumor.
How tumor cells turn off E-selectin and how imiquimod turns it back on are not yet known, 
but both effects required neighboring antigen-presenting cells (APCs) in the tumor. After imiquimod 
treatment, most APCs were mature dendritic cells—the most potent T cell stimulators. The effects 
of topical imiquimod on T reg cells are temporary, but may last just long enough to allow killer T 
cells to destroy the tumor without throwing off the normal balance of T cells in the skin. RB
Tardy DCs to the (Th1) rescue
In newborns, the sluggish appearance of one cell population means death to another, according 
to Lee et al. on page 2269. These results may help explain why newborns are highly susceptible 
to certain infections.
Newborn mice exposed to antigen respond by activating both T helper (Th)-1 and Th2 cells. 
Yet a second exposure causes allergy-promoting Th2 cells to thrive but microbe-fighting Th1 cells 
to die. Previous work by this group showed that antigen exposure during the first few days of life 
caused Th1 cells to express the cytokine receptor chain IL-13R1, a receptor not commonly found 
on these cells, which then teamed up with the IL-4R chain. The resulting heteroreceptor induced 
Th1 cell death when triggered by Th2-promoting IL-4 during secondary antigen exposure.
At six days of age, the authors now show, Th1 cells had a reversal of fortune. The turning 
point was marked by the appearance of a subset of antigen-presenting CD8+ dendritic cells 
(DCs) that churned out life-saving IL-12. Giving newborns extra IL-12, which is feebly produced 
before day 6, or providing them with IL-12–producing DCs blunted the expression of IL-13R1 
and rescued the Th1 cells. What delays the development of this DC population relative to other 
subsets remains unknown. RB
CAR keeps up the (heart) beat
A cell contact protein found in the heart does more than provide structural support, according to 
Lisewski et al. (page 2369). It also helps maintain a steady heartbeat.
In developing or injured heart muscle, a cell–cell adhesion protein known as the Coxsackievirus–
adenovirus receptor (CAR) helps growing muscle fibers stick to each other and settle into place. 
The relatively low levels of CAR in adult hearts suggest that they’ve outgrown the need for it. 
But the authors now find that this bit of CAR keeps ion channels called connexins in place, thus 
aiding the transmission of electrical connections between heart cells.
Decreasing CAR expression in the heart, the group found, did not disrupt the structural 
stability of the organ but triggered an erratic heartbeat. Electrical signals within each heart chamber 
were normal, but they were delayed in passing from atria to ventricles.
Electrical signals pass between the chambers through a cell cluster called the atrial-ventricular 
(AV) node, via ion channels made of connexins 45. The AV node cells of CAR-deficient mice 
had fewer of these connexins, which drifted throughout the cell membrane instead of clustering 
The loss of CAR (green) expression 
leads to cardiac arrhythmia because 
connexins (red) are no longer held in 
place at heart AV nodes.
Imiquimod induces the expression 
of E-selectin (yellow) on blood 
vessels in skin tumors.
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at gap junctions, where they belong. Although it’s possible that CAR-driven signals induce 
connexin gene expression, the recent discovery that the two proteins bind to each other suggests 
instead that CAR might pin down connexins in adjacent gap junctions, thereby preventing their 
mislocalization and subsequent degradation.
The findings might explain the association between cardiac arrhythmia and CAR loss seen in 
patients who develop autoantibodies against CAR or who become infected with Coxsackievirus. 
The group is now trying to confirm that this arrhythmia is due to a connexin disturbance at the 
AV node. HB
The lowdown on sugar highs
Short-lived sugar highs might give a quick energy boost, but according to El-Osta et al. (page 2409), 
they also leave a lasting bad impression on heart vessels of diabetes patients. The findings might 
explain why diabetics are at higher risk for heart disease.
Diabetes is a major cause of heart attack and stroke—events that are triggered by atherosclerotic 
plaques and inflammation in the arteries. In diabetic patients who have had extended periods of 
high blood glucose levels, arterial damage persists long after insulin therapy reduces their mean 
glucose levels. The authors now provide a molecular explanation for this phenomenon.
The group found that short-lived sugar highs, which occur even in insulin-treated diabetics, 
trigger histone modifications—an established effect of long-lasting sugar highs. Persistently high 
sugar levels are known to create reactive oxygen species that induce the generation of 
methylglyoxal—an activator of the histone methylating enzyme Set7. The authors found that brief 
blood sugar peaks also activated Set7, which bound to the promoter of the gene for NF-B, thereby 
increasing its expression. NF-B then switched on genes for proteins that help recruit and attach 
plaque-forming monocytes to vessel walls. These gene expression changes, which were seen in 
both human heart endothelial cells and mouse aortas, persisted for at least six days after glucose levels 
returned to normal. These changes were prevented by blocking methylglyoxal production.
Current treatments for diabetes are aimed at reducing mean glucose levels in patients but not 
the temporary rises in blood sugar levels that occur between insulin injections. This study suggests 
that adjusting the timing of the treatment regimen to avoid these spikes might be more effective 
in reducing the risk of heart disease. HB
Egr-2 prevents self-reactions
Self-tolerance is well known to be enforced in part by an external force of regulatory T cells. 
Now, Zhu et al. (page 2295) show that T cells also have their own internal barrier to self-
reactivity—a transcription factor called Egr-2.
The team had previously found that Egr-2 is made by T cells that are repeatedly stimulated by 
their cognate antigen. The cells then become unresponsive, much like T cells that are constantly 
exposed to self-antigens in the periphery.
The authors now find that, in mice, Egr-2 expression is also turned on in effector T cells that 
develop as a result of exposure to gut bacteria or to certain self-antigens. The Egr-2–expressing 
cells reacted to strong T cell receptor stimulation in vitro but did not trigger autoimmunity or 
responses against the gut bacteria in mice, suggesting that Egr-2 might only temper T cell reaction 
to the relatively weak signals of self-antigens. But how repeated antigen stimulation induces Egr-2 
and how the transcription factor distinguishes weak, self-signals from strong, non-self signals are 
not yet known.
The deletion of Egr-2 triggered the accumulation of effector T cells and the development of 
lupus and its accompanying inflammation. The T cells amassed due to reduced expression of the 
gene for the cell cycle inhibitor p21Cip1, one of the few known Egr-2 targets. The rapidly 
proliferating T cells overexpressed genes for inflammatory cytokines, but the authors have yet to 
determine which Egr-2–induced genes normally suppress these cytokine genes.
Persistent viral antigens are known to induce tolerance in effector T cells, resulting in chronic 
infections. The group is now investigating whether deletion of Egr-2 in these cells prevents 
chronic infection. HB
Cells exposed to high glucose (HG) 
levels overexpress NF-B due to 
histone modifications of the NF-B 
promoter by the enzyme Set7.
Overproliferating T cells infiltrate 
the liver and trigger lupus-like 
autoimmunity in older 
Egr-2–deficient mice.